Raquel von Schumann

Evangelisches Krankenhaus Bethesda Mönchengladbach

关注

立即认领

关注

立即认领

基本信息

浏览量：0

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 18 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

时间

引用量

主题

期刊级别

合作者

合作机构

Neoadjuvant Dynamic Marker-Adjusted Personalized Therapy Comparing Trastuzumab-Deruxtecan Versus Pacli-/Docetaxel + Carboplatin + Trastuzumab + Pertuzumab in HER2+ Early Breast Cancer: WSG-ADAPT-HER2-IV

Nadia Harbeck,Michael Braun,Oleg Gluz,Peter Schmid,Monika Karla Graeser,Andreas D. Hartkopf,Oliver Hoffmann,Athina Kostara,Silke Polata,Lea Louise Volmer,Raquel von Schumann,Sarah Wetzig,Stefanie Wiebe, Matthias R. Zaiss,Lotta Ada Fischer,Iris Scheffen,Matthias Christgen,Hans Heinrich Kreipe,Ulrike Nitz,Sherko Kuemmel

Journal of Clinical Oncologyno. 16_suppl (2024): TPS631-TPS631

引用0浏览0引用

Abstract PS09-01: Individual patient data meta-analysis of clinical and translational biomarkers for prediction of pathological complete response (pCR) after de-escalated therapy in HER2+ breast cancer in four trials of the West German Study Group

Monika Graeser,Oleg Gluz,Christine zu Eulenburg,Sherko Küemmel,Raquel von Schumann,Matthias Christgen,Rachel Wuerstlein,Enrico Pelz,Hans-Heinrich Kreipe,Peter Schmid,Marc Thill,Michael Braun,Jochem Potenberg,Claudia Schumacher,Joke Tio,Andreas Hartkopf,Marianne Just,Christian Schem,Kerstin Lüdtke-Heckenkamp,Eva-Maria Grischke,Felix Hilpert,Angela Kentsch,Ronald Kates,Ulrike Nitz,Nadia Harbeck

Cancer Researchno. 9_Supplement (2024): PS09-01

引用0浏览0引用

De-Escalated Neoadjuvant Trastuzumab-Emtansine With or Without Endocrine Therapy Versus Trastuzumab With Endocrine Therapy in HR1/HER21 Early Breast Cancer: 5-Year Survival in the WSG-ADAPT-TP Trial

Nadia Harbeck,Ulrike A. Nitz,Matthias Christgen,Sherko Kuemmel,Michael Braun,Claudia Schumacher,Jochem Potenberg,Joke Tio,Bahriye Aktas,Helmut Forstbauer,Eva-Maria Grischke,Iris Scheffen,Wolfram Malter,Raquel von Schumann,Marianne Just,Christine zu Eulenburg,Claudia Biehl,Cornelia Kolberg-Liedtke,Regula Deurloo,Sanne de Haas,Katarzyna Jozwiak,Michael Hauptmann,Ronald Kates,Monika Graeser,Rachel Wuerstlein,Hans H. Kreipe,Oleg Gluz

JOURNAL OF CLINICAL ONCOLOGY（2023）

引用0浏览0引用

Nab-paclitaxel Weekly Versus Dose-Dense Solvent-Based Paclitaxel Followed by Dose-Dense Epirubicin Plus Cyclophosphamide in High-Risk HR+/HER2− Early Breast Cancer: Results from the Neoadjuvant Part of the WSG-ADAPT-HR+/HER2− Trial

Sherko Kuemmel,Oleg Gluz,Ulrike Nitz,Michael Braun,Matthias Christgen,Kerstin Luedtke-Heckenkamp,Raquel Von Schumann,Maren Darsow,Helmut Forstbauer,Jochem Potenberg,Eva-Maria Grischke,Bahriye Aktas,Claudia Schumacher,Ronald Kates,Monika Graeser,Rachel Wuerstlein,Christoph Uleer,Michael Hauptmann,Steve Shak,Rick Baehner,Hans Kreipe,Nadia Harbeck

Annals of Oncology（2023）

引用16浏览0WOS引用

Efficacy of Endocrine Therapy Plus Trastuzumab and Pertuzumab vs De-escalated Chemotherapy in Patients with Hormone Receptor-Positive/ERBB2-Positive Early Breast Cancer The Neoadjuvant WSG-TP-II Randomized Clinical Trial

Oleg Gluz,Ulrike A. Nitz,Matthias Christgen,Sherko Kuemmel,Johannes Holtschmidt,Johannes Schumacher,Andreas Hartkopf,Jochem Potenberg, Kerstin Lueedtke-Heckenkamp,Marianne Just,Christian Schem,Raquel von Schumann,Cornelia Kolberg-Liedtke,Christine Zu Eulenburg,Timo Schinkoethe,Monika Graeser,Rachel Wuerstlein,Ronald E. Kates,Hans Heinrich Kreipe,Nadia Harbeck

JAMA ONCOLOGY（2023）

引用0浏览0WOS引用

Efficacy of Endocrine Therapy Plus Trastuzumab and Pertuzumab Vs De-escalated Chemotherapy in Patients with Hormone Receptor–Positive/ERBB2-Positive Early Breast Cancer

Oleg Gluz,Ulrike Nitz,Matthias Christgen,Sherko Küemmel,Johannes Holtschmidt,Johannes Schumacher,Andreas Hartkopf,Jochem Potenberg,Kerstin Luedtke‐Heckenkamp,Marianne Just,Christian Schem,Raquel von Schumann,Cornelia Kolberg‐Liedtke,Christine zu Eulenburg,Timo Schinköthe,Monika Graeser,Rachel Wuerstlein,Ronald Kates,Hans Kreipe,Nadia Harbeck

JAMA oncologyno. 7 (2023): 946-946

引用2浏览0引用

De-Escalated Neoadjuvant Trastuzumab-Emtansine with or Without Endocrine Therapy Versus Trastuzumab with Endocrine Therapy in HR+/HER2+ Early Breast Cancer: 5-Year Survival in the WSG-ADAPT-TP Trial

Journal of clinical oncology（2023）

引用0浏览0WOS引用

Immune Markers and Tumor-Related Processes Predict Neoadjuvant Therapy Response in the WSG-ADAPT HER2-Positive/Hormone Receptor-Positive Trial in Early Breast Cancer

Nadia Harbeck,Raquel von Schumann,Ronald Ernest Kates,Michael Braun,Sherko Kuemmel,Claudia Schumacher,Jochem Potenberg,Wolfram Malter,Doris Augustin,Bahriye Aktas,Helmut Forstbauer,Joke Tio,Eva-Maria Grischke,Claudia Biehl,Cornelia Liedtke,Sanne Lysbet De Haas,Regula Deurloo,Rachel Wuerstlein,Hans Heinrich Kreipe,Oleg Gluz

Cancers（2021）

引用14浏览0WOS引用

Abstract GS4-03: Neoadjuvant Nab-Paclitaxel Weekly Versus Dose-Dense Paclitaxel Followed by Dose-Dense EC in High Risk HR+/HER2- Early BC By: Results from the Neoadjuvant Part of ADAPT HR+/HER2- Trial

Sherko Kuemmel,Oleg Gluz,Ulrike Nitz,Michael Braun,Matthias Christgen,Kerstin Luedtke-Heckenkamp,Raquel von Schumann,Maren Darsow,Helmut Forstbauer,Jochem Potenberg,Eva-Maria Grischke,Bahriye Aktas,Claudia Schumacher,Ronald Kates,Monika Graeser,Rachel Wuerstlein,Christoph Uleer,Michael Hauptmann,Steve Shak,Rick Baehner,Hans Kreipe,Nadia Harbeck

Cancer research（2021）

引用6浏览0引用

Early Response By Mr Imaging And Ultrasound As Predictor Of Pathologic Complete Response To 12-Week Neoadjuvant Therapy For Different Early Breast Cancer Subtypes: Combined Analysis From The Wsg Adapt Subtrials

Monika Graeser,Simone Schrading,Oleg Gluz,Kevin Strobel,Rachel Würstlein,Sherko Kümmel,Claudia Schumacher,Eva-Maria Grischke,Helmut Forstbauer,Michael Braun,Matthias Christgen,Jascha Adams,Henrik Nitzsche,Marianne Just,Hans Holger Fischer,Bahriye Aktas,Jochem Potenberg,Raquel von Schumann,Cornelia Kolberg-Liedtke,Nadia Harbeck,Christiane K Kuhl,Ulrike Nitz

INTERNATIONAL JOURNAL OF CANCER（2021）

引用5浏览0WOS引用

加载更多

作者统计

#Papers: 19

#Citation: 290

H-Index: 6

G-Index: 13

Sociability: 5

Diversity: 2

Activity: 34

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn